A Novel Mechanism of Action Natural Product for Treatment of Drug-Resistant Gonorrhea
- Institution
- CFD RESEARCH CORPORATION, AL
- Principal investigator
- Aj Singhal
- Funding
- $289K
- Duration
- 2024–2026
Moonbase score
Still being scored
Abstract
Project Summary/Abstract: This project seeks to develop a new class of antibiotics against Neisseria gonorrhoeae (NG). NG is considered to be of the highest threat level by the CDC due to its propensity to rapidly develop drug resistance. CFD Research has discovered a novel natural product (NP) with potent NG activity, which we seek to develop here. Aim 1 will build on our established medicinal chemistry program to diversify and optimize the NP’s scaffold for improved potency, cytotoxicity and drug-like properties. Aim 2 will test the in vivo efficacy of the best analogues from Aim 1 in an established mouse model of NG infection. During Phase II, these data will drive further medicinal chemistry design and synthesis of a lead series. Mechanism of action will be elucidated. Followed by in vivo toxicity, and pharmacokinetics to produce an optimized lead compound for further preclinical development as a novel NG antibiotic.
LOADING MOONBASE SCORE
Questions for Cfd Research Corporation
Cfd Research Corporation hasn't set up its Moonbase portfolio yet, so questions about this research can't be asked here.
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Cfd Research CorporationNot yet scored
Controlled Release Eczema Bandage (CREB)
Aj Singhal · $50K · 2025–2026
- NIH · Cfd Research CorporationNot yet scored
Controlled Release Eczema Bandage (CREB)
Aj Singhal · $920K · 2021–2026
- NIH · Cfd Research CorporationNot yet scored
A high throughput alcohol screening platform (HT-ASP) incorporating cortical organoids.
Kevin Roehm · $500K · 2025–2026